Florian Janisch
Dr. med.
Florian Janisch
  • Assistenzarzt
  • Wissenschaftlicher Mitarbeiter



Hauptgebäude O10 , 2. Etage
Deutsch (Muttersprache)


  • 2021
  • 2020
  • 2019

Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021
Fankhauser C, Oldenburg J, Albers P, Algaba F, Bokemeyer C, Boormans J, Fischer S, Fizazi K, Gremmels H, Mayor de Castro J, Janisch F, Muilwijk T, Leão R, Nicol D, Nicolai N, Tandstad T, Pilar Laguna M
EUR UROL. 2021;80(1):4-6.

Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data
Janisch F, Kienapfel C, Fühner C, Klotzbücher T, Marks P, Hillemacher T, Meyer C, Iwata T, Parizi M, Sauter G, Fisch M, Shariat S, Dahlem R, Rink M
FRONT SURG. 2021;8:.

Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors
Janisch F, Klotzbücher T, Marks P, Kienapfel C, Meyer C, Yu H, Fühner C, Hillemacher T, Mori K, Mostafei H, Shariat S, Fisch M, Dahlem R, Rink M
WORLD J UROL. 2021;39(8):2977-2985.

Learning benefits of live surgery and semi-live surgery in urology-informing the debate with results from the International Meeting of Reconstructive Urology (IMORU) VIII
Schuettfort V, Ludwig T, Marks P, Vetterlein M, Maurer V, Fuehner C, Janisch F, Soave A, Rink M, Riechardt S, Engel O, Fisch M, Dahlem R, Meyer C
WORLD J UROL. 2021;39(7):2801-2807.

The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC)
Janisch F, D'Andrea D, Iwata T, Kimura S, Abufaraj M, Enikeev D, Glybochko P, Karakiewicz P, Nyirady P, Fajkovic H, Haitel A, Seebacher V, Rink M, Shariat S
UROL ONCOL-SEMIN ORI. 2020;38(5):423-432.

The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort
Janisch F, Hillemacher T, Fuehner C, D'Andrea D, Meyer C, Klotzbücher T, Kienapfel C, Vetterlein M, Kimura S, Abufaraj M, Dahlem R, Shariat S, Fisch M, Rink M
UROL ONCOL-SEMIN ORI. 2020;38(9):739.e9-739.e15.

The promise and challenges of neoadjuvant immunotherapy in the management of non-metastatic muscle-invasive bladder cancer
Janisch F, Rink M, Shariat S
BJU INT. 2020;125(6):753-755.

Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis
Janisch F, Shariat S, Baltzer P, Fajkovic H, Kimura S, Iwata T, Korn P, Yang L, Glybochko P, Rink M, Abufaraj M
WORLD J UROL. 2020;38(5):1165-1175.

Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer
Iwata T, Kimura S, Abufaraj M, Janisch F, Parizi M, Haitel A, Rink M, Rouprêt M, Fajkovic H, Seebacher V, Nyirady P, Karakiewicz P, Enikeev D, Rapoport L, Nasu Y, Shariat S
UROL ONCOL-SEMIN ORI. 2019;37(10):774-783.

Current Disease Management of Primary Urethral Carcinoma
Janisch F, Abufaraj M, Fajkovic H, Kimura S, Iwata T, Nyirady P, Rink M, Shariat S
EUR UROL FOCUS. 2019;5(5):722-734.

The interaction of gender and smoking on bladder cancer risks
Janisch F, Shariat S, Schernhammer E, Rink M, Fajkovic H
CURR OPIN UROL. 2019;29(3):249-255.

Do Younger Patients With Muscle-invasive Bladder Cancer Have Better Outcomes?
Janisch F, Yu H, Vetterlein M, Dahlem R, Engel O, Fisch M, Shariat S, Soave A, Rink M
J CLIN MED. 2019;8(9):.

The impact of variant histological differentiation on extranodal extension and survival in node positive bladder cancer treated with radical cystectomy
Marks P, Gild P, Soave A, Janisch F, Minner S, Engel O, Vetterlein M, Shariat S, Sauter G, Dahlem R, Fisch M, Rink M
SURG ONCOL. 2019;28:208-213.

Letzte Aktualisierung aus dem FIS: 05.12.2023 - 00:34 Uhr